Format

Send to

Choose Destination
Diabetes Care. 2019 Oct 11. pii: dc191071. doi: 10.2337/dc19-1071. [Epub ahead of print]

Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

Author information

1
Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL.
2
Internal Medicine, Department of Medicine, University of Florida, Gainesville, FL.
3
Quest Diagnostics Nichols Institute, San Juan Capistrano, CA.
4
Division of Gastroenterology, Hepatology and Nutrition, University of Florida, Gainesville, FL.
5
Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL.
6
Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL kenneth.cusi@medicine.ufl.edu.
7
Division of Endocrinology, Diabetes and Metabolism, Malcom Randall VA Medical Center, Gainesville, FL.

Abstract

OBJECTIVE:

The 2019 Standards of Medical Care in Diabetes suggested that patients with nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However, the performance of noninvasive clinical models/scores and plasma biomarkers for the diagnosis of nonalcoholic steatohepatitis (NASH) and advanced fibrosis has not been carefully assessed in patients with type 2 diabetes mellitus (T2DM).

RESEARCH DESIGN AND METHODS:

In this cross-sectional study, patients (n = 213) had a liver MRS, and those with a diagnosis of NAFLD underwent a percutaneous liver biopsy. Several noninvasive clinical models/scores and plasma biomarkers were measured to identify NASH and advanced fibrosis (NASH: alanine aminotransferase [ALT], cytokeratin-18, NashTest 2, HAIR, BARD, and OWLiver; advanced fibrosis: AST, fragments of propeptide of type III procollagen [PRO-C3], FIB-4, APRI, NAFLD fibrosis score, and FibroTest).

RESULTS:

None of the noninvasive tools assessed for the diagnosis of NASH in patients with T2DM had an optimum performance (all areas under the curve [AUCs] <0.80). Of note, none of the panels or biomarkers was able to outperform plasma ALT (AUC 0.78 [95% CI 0.71-0.84]). Performance was better to diagnose advanced fibrosis, in which plasma PRO-C3, AST, and APRI showed better results than the other approaches (AUC 0.90 [0.85-0.95]; 0.85 [0.80-0.91]; and 0.86 [0.80-0.91]; respectively). Again, none of the approaches did significantly better than plasma AST. Sequential use of plasma AST and other noninvasive tests may help in limiting the number of liver biopsies required to detect patients with advanced fibrosis.

CONCLUSIONS:

Performance of noninvasive clinical models/scores and plasma biomarkers for the diagnosis of NASH or advanced fibrosis was suboptimal in patients with T2DM. Combination of multiple tests may provide an alternative to minimize the need of liver biopsies to detect fibrosis in these patients.

PMID:
31604692
DOI:
10.2337/dc19-1071

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center